News | December 25, 2025
Tanabe Pharma America transfers RADICAVA business to Shionogi
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Nearly 6,000 patients have been treated with the drug since 2017
The product is used to treat amyotrophic lateral sclerosis
Subscribe To Our Newsletter & Stay Updated
